Sandoz Signs an Agreement with EirGenix to Commercialize Proposed Trastuzumab Biosimilar for HER2+ Cancer Tumors

Shots:

• EirGenix to receive upfront, milestones with profit sharing on sales and will be responsible for the development & manufacturing of proposed biosimilar trastuzumab. Sandoz to get WW rights to commercialize the proposed biosimilar trastuzumab (Ex- China & Taiwan)
• The agreement is the third biosimilar collaboration for Sandoz in 18 months, which will further focus on the expansion of its oncology portfolio with four oncology biosimilars
• Proposed trastuzumab biosimilar is been evaluated in P-III study for HER2+ breast and gastric cancer tumors. Additionally, Sandoz has 8 approved biosimilars and 10+ in the development phase for oncology, supportive cancer care, and hematology

Click here to read full press release/ article | Ref: Sandoz | Image: Behance